MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Nektar Therapeutics (NASDAQ:NKTR)*
Organization & Developments: Nektar Therapeutics
Parents
Nektar Therapeutics (NASDAQ:NKTR)*
Children
2012: Nektar Therapeutics and Amgen have entered into a non-exclusive agreement that will allow Nektar to manufacture and supply proprietary polymer material to Amgen used to make the company’s Neulasta drug
2017: Notable BioSci Mover On Dec. 7, 2017 - Nektar Therapeutics - Nektar Therapeutics (NASDAQ:NKTR)
2018: Bristol-Myers and Nektar Therapeutics team up to develop cancer combination treatments across nine tumor types; Nektar down 5% premarket_seekingalpha.com
2018: Nektar Stock Tries To Recover From Dive On Melanoma Study With Bristol
2019: How Nektar Could Climb Close To Old Highs - Nektar Therapeutics (NASDAQ:NKTR)
2019: Nektar_Biotech Crashes 29% After Bad Drug Likely Skewed Cancer Tests_www.investors.com
2019: Nektar: Robust Data Presented At ASCO 2019_seekingalpha.com
2020: Nektar abandons opioid drug after a unanimous 27-0 rebuff from FDA adcomm – Endpoints News
2020: Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates_endpts
2020: Nektar Therapeutics: A Look At The SITC BEMPEG Data
2020: Nektar Therapeutics: Updates To Thesis, Bempeg To Boost Opdivo Prospects In Crowded I-O Arena_seekingalpha.com
2021: Nektar Therapeutics Breaks Out On Combo Study With Merck's Keytruda
2022: Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flops
2022: Nektar Therapeutics: Recovery Seems To Be A Mirage_ seekingalpha.com
2022: UPDATE: Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
2024: Multiple Catalysts Ahead For Nektar Therapeutics
2024: Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
2025: Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
2025: REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
Jumps
*Key People: Nektar Therapeutics
Finance & Acquisitions: Nektar Therapeutics